Design Therapeutics, Inc.(DSGN)

$13.52—Stale · unknown old

Ask SA Chart

Design Therapeutics, Inc.(DSGN)

NASDAQ • Last print unknown ago

$13.52—Stale · unknown old

Ask SA Chart Studio

DSGN(DSGN)

DSGN

Q4 2026 EPS Estimate

$-0.38

Nov 4, 2026 · Reports before open

Analyst Sentiment

Wall St. Consensus

Buy

7 analysts·Limited coverage

Score

4 Buy (57%)3 Hold (43%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

457%

Hold

343%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$20.00

+47.9%

Consensus

$20.50

+51.6%

Bull

$21.00

+55.3%

12-Month Target Range7 analysts

$20.00$20.50$21.00

Current $13.52Consensus

Current Price

$13.52

Upside to Consensus

$6.98

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+74.53%

EPS—

FY2028

Rev-96.96%

EPS—

FY2029

Rev+974.74%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$117M	$205M	$6M	$67M	$248M
Low	$117M	$205M	$6M	$67M	$248M
High	$117M	$205M	$6M	$67M	$248M
EBITDA Avg	$-86M	$-116M	$-109M	$-93M	$-18M
Low	$-87M	$-120M	$-133M	$-93M	$-18M
High	$-66M	$-60M	$-86M	$-93M	$-18M
EBIT Avg	$-86M	$-116M	$-110M	$-93M	$-18M
Low	$-88M	$-120M	$-133M	$-93M	$-18M
High	$-66M	$-60M	$-86M	$-93M	$-18M
Net Income Avg	$-86M	$-116M	$-110M	$-93M	$-18M
Low	$-88M	$-120M	$-133M	$-93M	$-18M
High	$-66M	$-60M	$-86M	$-93M	$-18M
EPS Avg	$-1.33	$-1.56	$-1.96	$-1.62	$-0.32
Low	$-1.53	$-2.10	$-2.32	$-1.62	$-0.32
High	$-1.16	$-1.05	$-1.50	$-1.62	$-0.32
Analysts (Rev / EPS)	7 / 5	7 / 5	7 / 6	3 / 3	5 / 2

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027	Q1 2028	Q2 2028
Revenue Avg	—	—	—	—	—	—	—	—
Low	—	—	—	—	—	—	—	—
High	—	—	—	—	—	—	—	—
EBITDA Avg	—	—	—	—	—	—	—	—
Low	—	—	—	—	—	—	—	—
High	—	—	—	—	—	—	—	—
EBIT Avg	—	—	—	—	—	—	—	—
Low	—	—	—	—	—	—	—	—
High	—	—	—	—	—	—	—	—
Net Income Avg	$-22M	$-24M	$-22M	$-23M	$-24M	$-25M	$-35M	$-35M
Low	$-22M	$-29M	$-22M	$-23M	$-24M	$-25M	$-35M	$-35M
High	$-20M	$-18M	$-22M	$-23M	$-24M	$-25M	$-35M	$-35M
EPS Avg	$-0.34	$-0.39	$-0.35	$-0.36	$-0.39	$-0.41	$-0.56	$-0.56
Low	$-0.35	$-0.47	$-0.35	$-0.36	$-0.39	$-0.41	$-0.56	$-0.56
High	$-0.33	$-0.30	$-0.35	$-0.36	$-0.39	$-0.41	$-0.56	$-0.56
Analysts (Rev / EPS)	— / 4	— / 4	— / 1	— / 1	— / 1	— / 1	— / 2	— / 2

Earnings Surprises

Recent Analyst Actions

May 4, 2026Oppenheimer

Design Therapeutics price target raised to $21 from $18 at Oppenheimer

Target:$21.00

+57.9%from $13.30

Apr 29, 2026Piper Sandler

Design Therapeutics price target raised to $20 from $12 at Piper Sandler

Target:$20.00

+31.2%from $15.24

Jan 7, 2026Oppenheimer

Design Therapeutics initiated with an Outperform at Oppenheimer

Target:$18.00

+104.1%from $8.82

Dec 3, 2025Craig-Hallum

Design Therapeutics initiated with a Buy at Craig-Hallum

Target:$15.00

+67.8%from $8.94

Dec 3, 2025Leerink Partners

Design Therapeutics upgraded to Outperform from Market Perform at Leerink

Target:$14.00

+56.6%from $8.94

May 7, 2024Piper Sandler

Piper Sandler Upgrades Design Therapeutics Inc (DSGN) to Overweight

Target:$12.00

+228.8%from $3.65

Aug 15, 2023RBC Capital

Design Therapeutics' Modified DT-216 May Have Potential, But Analyst Awaits Further Developments

Target:$7.00

+223.3%from $2.17

Dec 7, 2022Piper Sandler

Design Therapeutics' DT-216 phase 1 data looks promising, says Piper Sandler

Target:$42.00

+231.0%from $12.69

May 2, 2022RBC Capital

RBC Capital Initiates Coverage On Design Therapeutics with Outperform Rating, Announces Price Target of $30

Target:$30.00

+151.3%from $11.94

Jan 19, 2022Goldman Sachs

Design Therapeutics Stock (DSGN): $10 Price Target From Goldman Sachs

Target:$10.00

-28.5%from $13.98

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance